Slika omota

A Pharmacokinetic Dose-Optimization Study of Cabotegravir and Bictegravir in a Mouse Pregnancy Model

Animal pregnancy models can be useful tools to study HIV antiretroviral safety and toxicity and to perform mechanistic studies that are not easily performed in humans. Utilization of clinically relevant dosing in these models improves the relevance of the findings. Cabotegravir and bictegravir are n...

Spremljeno u:

Bibliografski detalji
Glavni autori:	Haneesha Mohan (Autor), Kieran Atkinson (Autor), Birgit Watson (Autor), Chanson J. Brumme (Autor), Lena Serghides (Autor)
Format:	Knjiga
Izdano:	MDPI AG, 2022-08-01T00:00:00Z.
Teme:	article
Online pristup:	Connect to this object online.
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!

Slični predmeti

Dose-Ranging Plasma and Genital Tissue Pharmacokinetics and Biodegradation of Ultra-Long-Acting Cabotegravir In Situ Forming Implant
od: Isabella C. Young, i dr.
Izdano: (2023)

Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans
od: Hannah Kinvig, i dr.
Izdano: (2023)

Comparison of the Effects of Three Dual-Nucleos(t)ide Reverse Transcriptase Inhibitor Backbones on Placenta Mitochondria Toxicity and Oxidative Stress Using a Mouse Pregnancy Model
od: Kayode Balogun, i dr.
Izdano: (2022)

Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment: Efficacy and Tolerability in Clinical Practice
od: Canetti D, i dr.
Izdano: (2023)

Bictegravir and Metformin Drug-Drug Interaction in People with Human Immunodeficiency Virus (HIV)
od: Anne M. Masich, i dr.
Izdano: (2023)

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function
od: Chang Huang, i dr.
Izdano: (2023)

Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH)
od: Anna Gidari, i dr.
Izdano: (2023)

Experiences to date with the logistical management of long-acting cabotegravir and rilpivirine
od: Kamile Johnson, i dr.
Izdano: (2022)

Bictegravir Plus Tenofovir Alafenamide Nanoformulation as a Long-Acting Pre-Exposure Prophylaxis Regimen: Application of Modeling to Design Non-Human Primate Pharmacokinetic Experiments
od: Simone Perazzolo, i dr.
Izdano: (2020)

Phenobarbital Pharmacokinetics and Optimal Dosing of Phenobarbital
od: Safiullah Shareef, i dr.
Izdano: (2018)

Analysis of baseline laboratory characteristics of HIV-positive patients in Bulgaria treated with bictegravir /emtricitabine/ tenofovir anafelamide (early analysis)
od: Dimitar Strashimirov, i dr.
Izdano: (2024)

Method development and validation for Cabotegravir and Rilpivirine by using HPLC and its degradants are characterized by LCMS and FTIR
od: Anuradha Vejendla, i dr.
Izdano: (2021)

Population pharmacokinetics and dosing optimization of cefathiamidine in children with hematologic infection
od: Zhi LJ, i dr.
Izdano: (2018)

Population Pharmacokinetics and Dose Optimization of Ganciclovir in Critically Ill Children
od: SiChan Li, i dr.
Izdano: (2021)

Population pharmacokinetics and dose optimization of ceftazidime in critically ill children
od: Mengting Li, i dr.
Izdano: (2024)

An insight into pharmacokinetics and dose optimization of antimicrobials agents in elderly patients
od: Guanshuang Fu, i dr.
Izdano: (2024)

Population Pharmacokinetics and Dosing Regimen Optimization of Latamoxef in Chinese Children
od: Yang Wang, i dr.
Izdano: (2022)

Population pharmacokinetics and dose optimization of magnesium sulfate in Chinese preeclampsia population
od: Jing Deng, i dr.
Izdano: (2024)

Developmental Population Pharmacokinetics and Dosing Optimization of Cefepime in Neonates and Young Infants
od: Yang Zhao, i dr.
Izdano: (2020)

Population pharmacokinetics, dosing optimization and clinical outcomes of biapenem in patients with sepsis
od: Dayu Chen, i dr.
Izdano: (2024)

Population pharmacokinetics and dosing optimization of unbound teicoplanin in Chinese adult patients
od: Wen-Qian Fu, i dr.
Izdano: (2022)

Population Pharmacokinetics and Model-Based Dosing Optimization of Teicoplanin in Pediatric Patients
od: Tao Zhang, i dr.
Izdano: (2020)

Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study
od: Beatriz Grinsztejn, i dr.
Izdano: (2023)

Design and synthesis of cabotegravir derivatives bearing 1,2,3-triazole and evaluation of anti-liver cancer activity
od: Huaxia Xie, i dr.
Izdano: (2023)

Pharmacokinetic study of thymol after intravenous injection and high‐dose inhalation in mouse model
od: Kevin Xie, i dr.
Izdano: (2019)

Dosing optimization of rituximab for primary membranous nephropathy by population pharmacokinetic and pharmacodynamic study
od: Hao Liang, i dr.
Izdano: (2024)

Dosing Optimization of Posaconazole in Lung-Transplant Recipients Based on Population Pharmacokinetic Model
od: Eliška Dvořáčková, i dr.
Izdano: (2023)

Population pharmacokinetic analysis for dose regimen optimization of vancomycin in Southern Chinese children
od: Xianhuan Shen, i dr.
Izdano: (2024)

Population pharmacokinetic analysis and dosing optimization of polymyxin B in critically ill patients
od: Danhong Liang, i dr.
Izdano: (2023)

Development and Validation of Stability Indicating RP-HPLC Method for the Simultaneous Determination of Cabotegravir and Rilpivirine in Bulk and Injection Dosage Form
od: A Suneetha, i dr.
Izdano: (2022)

Strategies to reduce the wearing time of cabotegravir sodium dissolving microarray pacthes by facilitating fast tip detachment from the baseplate
od: Fabiana Volpe-Zanutto, i dr.
Izdano: (2022)

Lefamulin dosing optimization using population pharmacokinetic and pharmacokinetic/pharmacodynamic assessment in Chinese patients with community-acquired bacterial pneumonia
od: Xingchen Bian, i dr.
Izdano: (2024)

Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland
od: Paul Thoueille, i dr.
Izdano: (2022)

Population Pharmacokinetic Modeling and Dose Optimization of Vancomycin in Chinese Patients with Augmented Renal Clearance
od: Sixuan Zhao, i dr.
Izdano: (2021)

Physiologically based pharmacokinetic modeling of daptomycin dose optimization in pediatric patients with renal impairment
od: Lingling Ye, i dr.
Izdano: (2022)

Optimizing Antimicrobial Therapy by Integrating Multi-Omics With Pharmacokinetic/Pharmacodynamic Models and Precision Dosing
od: Hui-Yin Yow, i dr.
Izdano: (2022)

Population Pharmacokinetics of Caspofungin and Dosing Optimization in Children With Allogeneic Hematopoietic Stem Cell Transplantation
od: Chang-He Niu, i dr.
Izdano: (2020)

Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis
od: Chao‐Yang Chen, i dr.
Izdano: (2023)

Population Pharmacokinetic Modelling and Simulation to Determine the Optimal Dose of Nanoparticulated Sorafenib to the Reference Sorafenib
od: Ki-Young Huh, i dr.
Izdano: (2021)

Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in SwitzerlandResearch in context
od: Paul Thoueille, i dr.
Izdano: (2024)